For diabetes cases with cardiovascular risk, the 2024 ADA Standards of Care explicitly state: "In patients with type 2 diabetes and established cardiovascular disease or indicators of high cardiovascular risk, a GLP-1 receptor agonist with demonstrated cardiovascular benefit is recommended independently of baseline HbA1c, individualized HbA1c target, or metformin use" [6]
doi: 10.1002/smtd.202100115
This helps explain why GLP-1 drugs can reduce not only how much people eat, but also what they want to eat
[144] General studies and discussions on alcoholism throughout the mid-1900s were typically based on a heredity argument
Researchers at Pennsylvanias Penn State College of Medicine noted opioid use disorder (OUD), like other substance-use disorders, is widely understood to be a disorder of persistent relapse
Quality matters when youre delivering therapeutic doses directly to your bloodstream